First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

about

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

Item

http://www.wikidata.org/entity/Q47917650

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@en

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@nl

type

Item

label

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@en

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@nl

prefLabel

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@en

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@nl

P1476

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

@en

P2860

The concept of treatment-free remission in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

Chronic Myelogenous Leukemia (CML) in the elderly

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

P304

1-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1379074

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Saglio

Elias Jabbour

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28972424

http://www.w3.org/2001/XMLSchema#string